Predicting Effective Therapy in Pancreatic Cancer

Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response

The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.

Inclusion Criteria:

• Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment.
• Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents.
• Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted.
• ECOG performance status 0-2.
• A minimum age of 18 years old.

Exclusion Criteria:

• Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma
• Known to be HIV positive on antiretroviral therapy
• Prior organ allograft
• Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures